Rammensee H-G, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller K-H, Löffler MW. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. Vaccines (2021).

Fink S, Ruoff F, Stahl A, Becker M, Kaiser P, Traenkle B, Junker D, Weise F, Ruetalo N, Hörber S, Peter A, Nelde A, Walz J, Krause G, Baillot A, Schenke-Layland K, Joos TO, Rothbauer U, Schneiderhan-Marra N, Schindler M, Templin MF. Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2. ACS Infect Dis. (2021).

Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Rachfalski D, Märklin M, Stevanović S, Rammensee HG, Salih HR, Walz JS. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Transl Med. 13 (590):eabf7517 (2021).

Roerden M, Märklin M, Salih HR, Bethge WA, Klein R, Rammensee HG, Nelde A, Walz JS. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome. Leuk Lymphoma 2: 1-18 (2021).

Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, Dinter H, Häring J, Ghozzi S, Zeck A, Weise F, Peter A, Hörber S, Fink S, Ruoff F, Dulovic A, Bakchoul T, Baillot A, Lohse S, Cornberg M, Illig T, Gottlieb J, Smola S, Karch A, Berger K, Rammensee HG, Schenke-Layland K, Nelde A, Märklin M, Heitmann JS, Walz JS, Templin M, Joos TO, Rothbauer U, Krause G, Schneiderhan-Marra N. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun. 12(1):1152 (2021).

Nelde A, Rammensee HG, Walz JS. The Peptide Vaccine of the Future. Mol Cell Proteomics 20:100022 (2021)

Huergo LF, Selim KA, Conzentino MS, Gerhardt ECM, Santos ARS, Wagner B, Alford JT, Deobald N, Pedrosa FO, de Souza EM, Nogueira MB, Raboni SM, Souto D, Rego FGM, Zanette DL, Aoki MN, Nardin JM, Fornazari B, Morales HMP, Borges VA, Nelde A, Walz JS, Becker M, Schneiderhan-Marra N, Rothbauer U, Reis RA, Forchhammer K. Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies. ACS Sens. 6(3): 703-708 (2021)

Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber L-C, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 22(1):74-85 (2021)

Roerden M, Nelde A, Heitmann JS, Klein R, Rammensee HG, Bethge WA, Walz JS. HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. Cancers (Basel). 12(7):E1835 (2020).

Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med. 12(1):32 (2020).

Teck AT, Urban S, Quass P, Nelde A, Letsch A, Walz JS, Keilholz U, Ochsenreither S. Cancer testis Antigen Cyclin A1 habours several HLA-A*02:01-resticted T-cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2020 Mar 10.

Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee H-G, Stevanović S, and Walz JS. Mass spectrometry-based identification of a BCMA-derived T-cell epitope for antigen-specific immunotherapy in multiple myeloma. Blood Cancer J. Feb 28;10(2):24 (2020).

Lübke M, Spalt S, Kowalewski DJ, Zimmermann C, Bauersfeld L, Nelde A, Bichmann L, Marcu A, Peper JK, Kohlbacher O, Walz JS, Khanh Le-Trilling VT, Hengel H, Rammensee H-G, Stevanović S, and Halenius A. Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. J Exp Med (3):jem.20191164. (2020). 

Roerden, M, Nelde, A, Walz, JS (2019). Neoantigens in Hematological Malignancies – Ultimate Targets for Immunotherapy? Frontiers in Immunology 10: 3004

Bichmann, L, Nelde, A, Ghosh, M, Mohr, C, Peltzer, A, Kuchenbecker, L, Heumos, L, Sachsenberg, T, Walz, JS, Stevanović, S, Rammensee, H-G, and Kohlbacher, O (2019). MHCquant: Automated and reproducible data analysis for immunopeptidomics. Journal of Proteome Research 18(11): 3876-3884.

Roerden, M, Walz, JS, Müller, MR, Sökler, M, Federmann, B, Kanz, L, Bethge, W, Vogel, W (2019). The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience. J Cancer Res Clin Oncol 145(10):2595-2604

Bauer, J, Nelde, A, Bilich, T, Walz, JS (2019). Antigen Targets for the Development of Immunotherapies in Leukemia. Int J Mol Sci. 2019 Mar 20;20(6). 

Bilich, T*, Nelde, A*, Bichmann, L, Roerden, M, Salih, HR, Kowalewski, DJ, Schuster, H, Tsou, CC, Marcu, A, Neidert, MC, Lübke, M, Rieth, J, Schemionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Bauer, J, Märklin, M, Peper, JK, Klein, R, Kohlbacher, O, Kanz, L, Rammensee, HG, Stevanović, S, Walz, JS (2019). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133(6):550-565.

Kuželová, K, Brodská, B, Schetelig, J, Röllig, C, Ráčil, Z, Walz, JS, Helbig, G, Fuchs, O, Vraná, M, Pecherková, P, Šálek, C, Mayer, J (2018). Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.. PLoS One 13(12):e0204290.

Walz, JS, Kowalewski, DJ, Backert, L, Nelde, A, Kohlbacher, O, Weide, B, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2018). Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leuk Lymphoma 59(8):1949-1958.

Neidert, MC, Kowalewski, DJ, Silginer, M, Kapolou, K, Backert, L, Freudenmann, LK, Peper, JK, Marcu, A, Wang, SS, Walz, JS, Wolpert, F, Rammensee, HG, Henschler, R, Lamszus, K, Westphal, M, Roth, P, Regli, L, Stevanović, S, Weller, M, Eisele, G (2018). The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 135(6):923-938.

Nelde, A, Kowalewski, DJ, Backert, L, Schuster, H, Werner, JO, Klein, R, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S, Walz, JS (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology 7(4):e1316438.

Maurer, S, Kropp, KN, Klein, G, Steinle, A, Haen, SP, Walz, JS, Hinterleitner, C, Märklin, M, Kopp, HG, Salih, HR (2017). Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology 7(2):e1364827.

Schuster, H, Peper, JK, Bösmüller, HC, Röhle, K, Backert, L, Bilich, T, Ney, B, Löffler, MW, Kowalewski, DJ, Trautwein, N, Rabsteyn, A, Engler, T, Braun, S, Haen, SP, Walz, JS, Schmid-Horch, B, Brucker, SY, Wallwiener, D, Kohlbacher, O, Fend, F, Rammensee, HG, Stevanović, S, Staebler, A, Wagner, P (2017). The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 114(46):E9942-E9951.

Heidenreich, F, Rücker-Braun, E, Walz, JS, Eugster, A, Kühn, D, Dietz, S, Nelde, A, Tunger, A, Wehner, R, Link, CS, Middeke, JM, Stölzel, F, Tonn, T, Stevanovic, S, Rammensee, HG, Bonifacio, E, Bachmann, M, Zeis, M, Ehninger, G, Bornhäuser, M, Schetelig, J, Schmitz, M (2017). Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica 102(11):e460-e464. 

Liu, X, Pichulik, T, Wolz, OO, Dang, TM, Stutz, A, Dillen, C, Delmiro Garcia, M, Kraus, H, Dickhöfer, S, Daiber, E, Münzenmayer, L, Wahl, S, Rieber, N, Kümmerle-Deschner, J, Yazdi, A, Franz-Wachtel, M, Macek, B, Radsak, M, Vogel, S, Schulte, B, Walz, JS, Hartl, D, Latz, E, Stilgenbauer, S, Grimbacher, B, Miller, L, Brunner, C, Wolz, C, Weber, ANR (2017). Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol 140(4):1054-1067.e10.

Backert, L, Kowalewski, DJ, Walz, S, Schuster, H, Berlin, C, Neidert, MC, Schmeionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Kanz, L, Salih, HR, Kohlbacher, O, Weisel, K, Rammensee, HG, Stevanović, S, Walz, JS (2017). A meta-analysis of HLA peptidome composition in different hematological entities: Entity-specific dividing lines and “pan-leukemia” antigens. Oncotarget 8(27): 43915–43924.

Nelde, A, Stickel, JS, Kowalewski, DJ, Schuster, H, Wolz, O, Peper, JK, Gloria, YC, Langerak, AW, Muggen, AF, Claus, R, Bonzheim, I, Fend, F, Salih, HR, Kanz, L, Rammensee, H-G, Stevanović, S, Weber, ANR (2016). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology 2017;6(3):e1219825.

Kowalewski, DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee, HG, Stevanovic, S and Stickel, JS (2016). Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J 6: e411.

Werner JO*, Stickel JS*, M, Droppa, P, Krumm, MR, Müller, L, Kanz, F, Kreth (2016) Pericardial effusion as first manifestation of NSCLC. Ann Hematol Oncol. [In press]. 

Walz, S*, Stickel, JS*, Kowalewski, DJ, Schuster, H, Weisel, K, Backert, L, Kahn, S, Nelde, A, Stroh, T, Handel, M, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2015) The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell based immunotherapy. Blood. 2015 Sep 3;126(10):1203-13.

Kowalewski, DJ, Stevanovic, S, Rammensee, HG, Stickel, JS (2015) Anti-leukemia T cell responses in CLL – We don’t need no aberration. Oncoimmunology. 2015 Mar 16;4(7).

Kowalewski, DJ, Schuster, H, Backert, L, Berlin, C, Kahn, S, Kanz, L, Salih, HR, Rammensee, HG, Stevanovic, S, Stickel, JS (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous anti-leukemia immune responses in CLL. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75.

Berlin, C, Kowalewski, DJ, Schuster, H, Mirza, N, Walz, S, Handel, M, Schmid-Horch, B, Salih, HR, Kanz, L, Rammensee, HG, Stevanovic, S, & Stickel, JS (2015) Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015 Mar;29(3):647-59.

Stickel, JS, Mayer, F, Vollmer, JP, Zurn, CS, Gawaz, M, Kanz, L, & Bauer, A (2013) Ventricular thrombus and thrombocytopenia as first presentation of anaplastic thyroid carcinoma. J Clin Oncol 31(12):e194-196.

Seizer, P, Klingel, K, Stickel, J, Dorn, C, Horger, M, Kandolf, R, Bigalke, B, May, AE, Gawaz, M, & Schreieck, J (2013) Left ventricular site-directed biopsy guided by left ventricular voltage mapping: a proof of principle. Int J Cardiol 168(3):3113-3114. 

Bolla, D, Wiedemann, N, Ohlschlegel, C, Schoning, A, Stickel, J, Thurlimann, B, & Hornung, R (2011) Pseudoangiomatous stromal hyperplasia of breast in man: a case report. The breast journal 17(3):311-312.

Stickel, JS, Stickel, N, Hennenlotter, J, Klingel, K, Stenzl, A, Rammensee, HG, & Stevanovic, S (2011) Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol 11:1. 

Stickel, JS (2011) Tumorantigene des Nierenzellkarzinoms, Südwest-deutscher Verlag für Hochschulschriften, Book p 224

Stickel, JS, Weinzierl, AO, Hillen, N, Drews, O, Schuler, MM, Hennenlotter, J, Wernet, D, Muller, CA, Stenzl, A, Rammensee, HG, & Stevanovic, S (2009) HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 58(9):1407-1417.